XRF Scientific Limited Overview
XRF Scientific is a Perth-based, vertically integrated specialist in sample preparation for elemental analysis — the step that converts a raw ore, cement, steel or industrial sample into a homogeneous fused bead, pressed pellet or crushed aliquot that an XRF, ICP or combustion analyser can measure accurately. The company manufactures lithium borate fusion fluxes and laboratory chemicals (Consumables), automated fusion machines, furnaces, laboratory jaw crushers and analytical instruments (Capital Equipment), and platinum labware with an associated recycling service (Precious Metals). Its economic engine is a razor-and-blade model: a growing installed base of xrFuse fusion machines pulls through recurring flux sales and periodic platinum crucible recycling. Mining-sector sample testing remains the dominant demand driver, but management is deliberately broadening the instrument portfolio — Orbis crushers, xrTGA thermogravimetric analysers and, from April 2026, Bruker's former combustion gas analysis range — while expanding direct presence in India and the United States.
Company's own description
In its FY2026 Annual Report the company describes its principal activity as the manufacture and marketing of precious metal products, specialised chemicals and instruments for the scientific, analytical and mining industries, noting no significant change in the nature of activities during the year. Its standard corporate boilerplate (ASX announcements, 2026) states that XRF manufactures equipment and chemicals distributed to production mines, construction material companies and commercial analytical laboratories in Australia and overseas, used in the preparation of samples for analysis, with manufacturing, sales and support facilities in Australia, Europe, Canada and India, plus a global distributor network and representation in the United States, South America, Africa, the Middle East and Asia. Named blue-chip customers include BHP, Rio Tinto, Vale, South32, Glencore, Alcoa, Lafarge, Holcim, ArcelorMittal, CSIRO, Intertek, Bureau Veritas, SGS and ALS.
Revenue recognition (Note 1(e), FY2026): revenue is derived from manufacture and sale of chemicals, equipment and accessories, recognised at a point in time on delivery, plus service revenue from installation, maintenance and repair, some recognised over one- or two-year service contracts.
Revenue model mix
| Revenue type (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Sale of goods (A$m) | 39.29 | 54.29 | 58.31 | 57.71 | 62.56 |
| Service revenue point in time (A$m) | 0.46 | 0.59 | 1.18 | 1.04 | 1.26 |
| Service revenue over time (A$m) | 0.26 | 0.29 | 0.35 | 0.44 | 0.31 |
| Interest income (A$m) | 0.00 | 0.09 | 0.28 | 0.26 | 0.27 |
| Total revenue (A$m) | 40.01 | 55.26 | 60.12 | 59.45 | 64.40 |
Source: Note 5, FY2023, FY2025, FY2026 Annual Reports.
The business is overwhelmingly a product business (c.97.5% of external revenue in FY2026 from sale of goods). Services (installation, maintenance, repair) were c.2.5%. There is no subscription or licensing revenue. However, the economic character is more recurring than the product label suggests: consumable flux sales and platinum labware recycling are repeat purchases consumed in every analysis cycle. In 1H FY2023 management disclosed that ongoing spare parts and service revenue represented 27% of Capital Equipment revenue (Half-year presentation, Feb 2023). Consumables (A$18.1m FY2026) plus recycling-driven Precious Metals revenue imply that roughly half of group revenue is consumption-linked (analyst characterisation; recycling share of Precious Metals revenue is not separately disclosed).
Pricing mechanics. Precious Metals and Consumables both operate cost-plus or pass-through pricing on volatile inputs (platinum and lithium carbonate respectively). The FY2026 Annual Report notes that higher platinum prices increased customer prices for new products and recycling; the FY2025 report notes that falling lithium chemical prices reduced both selling prices and production costs. The company states in Note 2 that because customer commitments are at market rates, its commodity price exposure is immaterial. Revenue therefore moves with commodity prices while margin dollars are relatively insulated.
Value chain position
XRF sits in the pre-analytical segment of the analytical instrumentation value chain. Spectrometer OEMs (Thermo Fisher, Bruker, Malvern Panalytical, Rigaku, Hitachi) sell the measurement device; XRF supplies the consumables and equipment that prepare the specimen. Accuracy of borate fusion is a pre-requisite for high-precision XRF analysis of ores, cement and slags, making fluxes and platinumware critical-path inputs with low cost relative to the value of the analytical result. The company is vertically integrated: it fabricates platinum labware (Melbourne plant; Germany), blends and fuses lithium borate fluxes (Perth), designs and assembles fusion machines (Perth; xrTGA in Melbourne) and, through Orbis, laboratory crushers. The April 2026 CGA acquisition moves XRF one step further down the chain into the measurement layer itself (CS/OHN analysers).
Customer types and end-markets
| Customer type | Description | Evidence |
|---|---|---|
| Commercial analytical laboratories | Global testing houses (ALS, SGS, Bureau Veritas, Intertek) processing exploration and grade-control samples | Named customer list, ASX boilerplate |
| Production mines (on-site labs) | Iron ore, bauxite, nickel, copper, gold, lithium operations | FY2023–FY2026 operating commentary |
| Construction materials | Cement and aggregates producers (Lafarge, Holcim) | ASX boilerplate |
| Metals and steel | ArcelorMittal; iron, steel, aluminium, copper producers | ASX boilerplate; CGA application list |
| Industrial / research | Glass, ceramics, chemicals, petrochemicals, CSIRO, nuclear materials, rare-earth magnets, additive manufacturing | CGA acquisition announcement (Apr 2026) |
| New TGA verticals | Food, plastics, agricultural products quality control | FY2023 Annual Report (xrTGA launch) |
Independent characterisation
XRF is best understood as a mining-cycle-exposed, consumables-anchored niche industrial with an increasingly diversified instrument arm. Its moat rests on (i) installed-base lock-in (xrFuse machines specify XRF fluxes and platinumware), (ii) a claimed 50%+ share of the global fusion flux market (Morgans profile), (iii) in-house platinum fabrication and recycling capability that few competitors replicate at its scale in the Southern Hemisphere, and (iv) a capital-light, net-cash balance sheet funding bolt-on M&A. The principal vulnerabilities are concentration on mining sample volumes, small scale against diversified multinationals, and lumpy capital-equipment demand.
Strategy
Stated strategy (FY2026 Annual Report and FY2026 results)
The FY2026 Directors' Report states the group's objectives are to increase profitability and market capitalisation, with strategies comprising geographic expansion initiatives, new product development, and acquisition of complementary laboratory product manufacturing or supply companies. Recurring themes across FY2025–FY2026 disclosure:
-
International sales growth — described as a key focus, to be accelerated through new international offices and the CGA acquisition.
-
Cross-selling — customers increasingly buying multiple products across the range (fluxes, machines, platinumware, crushers, instruments).
-
Installed base monetisation — growing machine base generating recurring consumables, platinum recycling, spare parts and service revenue.
-
New products — xrTGA, next-generation xrFuse, Orbis line extensions, gold-sector products, and at least six new machines in advanced development.
-
Bolt-on M&A in adjacent sectors — value-accretive acquisitions funded from cash.
Initiatives register (last 24 months)
| Date | Initiative | Type | Detail / target | Status |
|---|---|---|---|---|
| Jul 2024 | Orbis 100% ownership | M&A | Remaining 50% for A$3.9m upfront plus earn-out (A$0.8m settled in shares FY2026) | Complete |
| Dec 2024 | Labfit acquisition | M&A | A$1.2m; CS and pH analysers, weighing systems | Integrated Mar 2025 qtr |
| FY2025 | STG Mining Supplies distribution (Americas) | Channel | Six countries; became leading external Orbis distributor | Active |
| FY2025–FY2026 | Melbourne platinum automation | Operational | Automation to lower cost and improve production technology | Ongoing |
| Sep 2025 qtr | Next-gen xrFuse 1 and 2 | Product | Launched; positive reception | Launched |
| Feb 2026 | India direct office | Geographic | Five staff; transition from distributor model | Profitable Sep 2026 qtr |
| FY2026 | USA direct office | Geographic | Opened; supports Orbis, CGA, consumables | Ramping |
| Apr 2026 | CGA acquisition from Bruker | M&A / product | US$4m upfront + up to US$1m earn-out | Integration; production in Perth from Dec 2026 qtr |
| Sep 2026 qtr | Orbis OM25 and Standalone RSD/LSD | Product | Smaller-lab crusher; standalone dividers | Released |
| Sep 2026 qtr | Closure of platinum inventory lease | Balance sheet | Off-balance-sheet lease no longer required | Complete |
| FY2027 | Growth priorities | Strategy | Ramp India and US offices; grow Orbis and xrTGA; launch CGA instruments and consumables; gold-sector product development | Guided |
Cost programmes and ESG commitments
No formal cost-reduction programme with quantified targets has been announced. The company references ongoing cost control and productivity improvements (FY2025 Chairman's letter) and automation at the Melbourne plant (FY2026). No quantified ESG or emissions targets have been published.
Medium-term targets and guidance
The company does not publish quantitative financial guidance; the FY2026 Annual Report states that likely results are not disclosed to avoid commercial prejudice. Qualitative guidance (13 October 2026): the December 2026 quarter is expected to be another strong period, with incremental CGA instrument revenue and significant Orbis growth. CGA revenue is expected from Q2 FY2027 once production has transferred to Perth.
Products & Services
Pricing for individual products is not publicly disclosed. Precious Metals and Consumables pricing broadly follows input-cost pass-through (platinum, lithium) per annual report commentary.
Consumables segment
| Product / brand | Description & capabilities | Target customer | Launch / latest version | Notes |
|---|---|---|---|---|
| Lithium borate fusion fluxes | Pre-fused lithium tetraborate / metaborate blends (with optional integrated non-wetting agents and oxidisers) used to dissolve oxide samples into homogeneous glass beads for XRF or into solution for ICP | Mining labs, commercial labs, cement, steel | Origin 1972; continuously developed | Core franchise; company cited as holding 50%+ of global fusion flux market (Morgans) |
| Patented copper-analysis flux | Special flux formulation for copper ore/concentrate analysis | Copper producers and labs | Used by Australian customers; first international sale FY2026 | Patented (FY2026 Annual Report) |
| xr-Tab binder tablets | Binder tablets for pressed-pellet sample preparation | XRF labs using pressed powders | Launched FY2023 | FY2023 Annual Report |
| Laboratory chemicals and supplies | Ancillary reagents, releasing agents, oxidisers, calibration materials | Analytical laboratories | Ongoing | Product catalogue (Jan 2024) |
| Calibration standards and drift monitors | Calibration sets, XRF drift monitors, customised fused beads | XRF laboratories | Ongoing | Product catalogue |
| Application kits and method development | Sample preparation and application kits for XRF and ICP; method development services | Labs establishing new methods | Ongoing | Product catalogue; David Brown consultancy (technical services) |
Capital Equipment segment
| Product / brand | Description & capabilities | Target customer | Launch / latest version | Notes |
|---|---|---|---|---|
| xrFuse fusion machines (incl. xrFuse 1, xrFuse 2 and multi-position models) | Electric automated fusion instruments producing glass beads for XRF and solutions for ICP | Mining, cement, steel, commercial labs | Next-generation xrFuse 1 and 2 launched FY2026 | Installed base drives flux and platinumware pull-through |
| High-temperature furnaces | Test and production furnaces, including loss-on-ignition applications | Labs and industrial users | Ongoing | Segment description FY2023 |
| xrTGA | Thermogravimetric analyser — heats samples to set temperatures while measuring mass change; applications in iron ore, bauxite, nickel, cement, and new verticals (food, plastics, agriculture) | Mining and industrial QC labs | Launched June 2023; first deliveries Dec 2023 quarter | Manufactured in Melbourne; A$1m sales in FY2026 |
| Orbis laboratory jaw crushers | Laboratory jaw crushers with patented component enabling large feed (up to c.110 mm) to be crushed to c.2 mm in a single pass | Commercial labs, mine-site labs, gold sector | Orbis founded 2014; OM25 compact crusher released Sep 2026 quarter | Increasingly integrated into robotic sample preparation cells |
| Orbis Standalone RSD / LSD | Rotary and linear sample dividers for representative sub-sampling | Commercial and mine labs | Released Sep 2026 quarter | ASX 13 Oct 2026 |
| Labfit carbon-sulphur analysers | Elemental analysis of carbon and sulphur in mining and industrial samples | Mining and industrial labs | Acquired Dec 2024 | FY2025 Annual Report |
| Labfit pH analysers | Measurement of acidity/alkalinity in water, soil and other samples | Environmental, agricultural, industrial labs | Acquired Dec 2024 | FY2025 Annual Report |
| Labfit laboratory weighing systems | Automated laboratory weighing | Labs | Acquired Dec 2024 | FY2025 Annual Report |
| CGA CS/OHN analysers (ex-Bruker) — four instruments incl. "G4 Icarus" | Rapid elemental analysis of carbon, sulfur, oxygen, hydrogen and nitrogen using three technologies: hot extraction, inert gas fusion, and combustion by induction heating | Nuclear energy materials, rare-earth magnets, powder metallurgy/additive manufacturing, welding, ores and minerals, glass, ceramics, cement, iron, steel, cobalt, nickel, copper, aluminium | Acquired Apr 2026; Perth production expected to commence Dec 2026 quarter | Product names such as G4 Icarus transferred and rebranded XRF Scientific; identities of the other three instruments not specified in XRF disclosure |
| Other sample-preparation equipment | Bench-top and laboratory equipment, drying ovens, general lab equipment | Labs | Ongoing | Product catalogue |
| Spare parts and service | Installation, maintenance contracts (1–2 years), repairs | Installed base | Ongoing | Note 1(e); service revenue A$1.57m FY2026 |
| Pipeline | "At least six new machines in advanced stages of development" for release through FY2027 and beyond; gold-sector product development | Various | FY2027+ | FY2026 Annual Report; FY2026 results |
Precious Metals segment
| Product / service | Description | Target customer | Notes |
|---|---|---|---|
| Platinum labware — crucibles | Pt/Au (typically 95/5) crucibles for fusion | XRF/ICP labs | Often sold alongside new fusion machines |
| Platinum labware — moulds / casting dishes | Moulds for casting fused glass beads | XRF labs | Precision fabrication in Melbourne |
| Labware recycling / refabrication | Spent platinumware returned, refined and refabricated; recurring with sample volumes | Mining and commercial labs | Described as at "positive levels" in Sep 2026 quarter |
| Industrial platinum alloy products | Customised platinum alloy products for industrial users (e.g., European industrial customers served from Germany) | Industrial manufacturers | Germany office revenue A$7.3m FY2023 |
| Metal sales | Occasional sale of metal (e.g., A$2.05m one-off sale in Sep 2026 quarter on closure of a platinum inventory lease, margin A$0.1m) | Lessors / counterparties | Non-recurring |
Financial Narrative
All figures A$m, fiscal years ended 30 June, from audited annual reports (FY2023 report for FY2022–FY2023; FY2025 report for FY2024–FY2025; FY2026 report for FY2026). Ratios derived.
Income statement
Notes: FY2026 adjusted PBT excludes A$0.69m of CGA acquisition costs and India/USA office set-up costs. Discrepancy flag: the FY2025 Directors' Report narrative states NPAT attributable to members of A$10,337,596 in one sentence and A$10,383,453 in the results table; the audited income statement confirms A$10,383,453 attributable and A$10,337,596 total NPAT (the NCI absorbed a A$45,857 loss). FY2023 PBT is A$11.79m statutory; the results release quoted A$11.1m because it was presented net of the Orbis non-controlling interest.
Margins and growth (derived)
FY2022 revenue growth calculated against FY2021 total revenue of A$31.29m (sales) as reported in FY2023 Annual Report charts; FY2022 NPAT growth against FY2021 NPAT of A$5.13m.
Compound growth (derived): FY2022–FY2026 total revenue CAGR 12.6%; sales revenue CAGR 12.5%; NPAT attributable CAGR 14.6%; EPS CAGR 13.2%; DPS CAGR 15.8%; EBITDA CAGR 15.7%.
Commentary. The five-year profile has two distinct phases. FY2022–FY2023 was volume-led hypergrowth: revenue rose 38% in FY2023 on record fusion-machine orders, rising lithium-driven flux prices and Orbis consolidation, while gross margin actually compressed (to 41.6%) as pass-through pricing inflated revenue faster than margin dollars. FY2024–FY2026 was margin-led: revenue grew only 7% cumulatively over FY2024–FY2026's first two years while gross margin expanded c.770bp to 49.3% in FY2026, driven by (i) falling lithium input costs reducing both price and cost (mechanically lifting percentage margin), (ii) product mix toward higher-margin Orbis and instruments, and (iii) productivity gains in the Melbourne platinum plant. The FY2026 inflection is that operating leverage stalled: gross profit rose A$2.9m but administration, occupancy and other expenses rose A$2.3m combined, reflecting new offices, CGA integration and a A$0.9m rise in employee benefits expense. Statutory NPAT therefore grew only 1%, though adjusted PBT grew 10%. The effective tax rate also rose to 31.8% on non-deductible acquisition costs and sundry items.
Balance sheet
Negative net debt denotes a net cash position. Borrowings at 30 June 2026 consist of a property loan (A$0.94m) for the Melbourne platinum factory; remaining platinum loans of A$0.7m were repaid early in FY2026 owing to high interest cost.
Commentary. The balance sheet is conservative and has strengthened every year except FY2026, when cash fell A$2.8m because the A$5.6m CGA cash consideration was funded internally. Inventory is the dominant asset (27% of total assets in FY2026) and grew A$2.2m in FY2026, primarily raw materials and spare parts (A$11.0m vs A$8.9m), consistent with CGA stock (A$0.7m acquired) and new-product build. Intangibles rose A$6.6m on CGA (goodwill A$4.40m; acquired development assets A$1.79m). A A$1.4m earn-out provision was recognised. Equity grew A$6.2m despite A$6.4m of declared dividends, aided by DRP issuance and the A$0.8m Orbis earn-out settled entirely in shares.
Cash flow
Commentary. Cash conversion has normalised to around 1.0x NPAT after the FY2022 trough (0.52x), when rising lithium prices and machine build absorbed working capital. Capex remains modest at 2.6–4.0% of revenue, confirming a capital-light model. Capitalised R&D stepped up in FY2025–FY2026 (A$0.40m to A$0.76m), aligned with the six-machine development pipeline. FCF after leases of A$8.0m in FY2026 covered cash dividends (A$5.0m) 1.6x; the remaining cash plus opening balance funded CGA. No buybacks have been undertaken; the DRP is the preferred capital-retention mechanism.
Returns, leverage and efficiency ratios (derived)
Invested capital = total equity + borrowings + lease liabilities − cash. NOPAT = EBIT × (1 − effective tax rate). DIO/DPO computed on cost of sales; payables include other payables, so DPO is approximate.
Commentary. Returns are solid rather than spectacular for a niche industrial, peaking at c.20% ROIC in FY2024–FY2025. The FY2026 dip to 17.5% reflects the A$5.6m CGA investment entering invested capital before generating revenue (expected from Q2 FY2027). The standout weakness is the very long cash conversion cycle (c.200–250 days), structurally driven by precious-metal inventory (platinum held for fabrication) and a broad spare-parts and raw-materials holding across many SKUs. The progressive replacement of leased platinum with owned metal over the past decade (culminating in closure of the last off-balance-sheet lease in the September 2026 quarter) improves resilience but increases inventory days. Leverage is negligible and the business is effectively ungeared.
Quarterly trading cadence (unaudited, from quarterly trading reports)
Q2FY25 and Q4FY25 revenue derived by subtraction from half-year and full-year totals. Q4FY26 PBT shown statutory (derived: FY26 PBT less 9M PBT); company-reported adjusted Q4FY26 PBT was A$4.7m. Q1FY27 includes a one-off A$2.05m metal sale (margin A$0.1m); excluding it, revenue grew 25%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total revenue (AUD Mn) | 40.01 | 55.26 | 60.12 | 59.45 | 64.40 |
Sales revenue — external customers (AUD Mn) | 40.01 | 55.17 | 59.84 | 59.19 | 64.13 |
Cost of sales (AUD Mn) | 22.69 | 32.28 | 33.57 | 30.65 | 32.68 |
Gross profit (AUD Mn) | 17.32 | 22.98 | 26.55 | 28.79 | 31.72 |
Administration expenses (AUD Mn) | 7.76 | 9.17 | 10.86 | 11.84 | 13.18 |
Occupancy expenses (AUD Mn) | 0.77 | 0.97 | 0.95 | 1.09 | 1.26 |
Other expenses (AUD Mn) | 0.56 | 0.88 | 1.00 | 1.05 | 1.83 |
Finance costs (AUD Mn) | 0.07 | 0.22 | 0.29 | 0.26 | 0.13 |
EBIT — derived (AUD Mn) | 8.26 | 11.92 | 13.47 | 14.58 | 15.23 |
Depreciation and amortisation (AUD Mn) | 1.18 | 1.20 | 1.57 | 1.69 | 1.71 |
EBITDA — derived (AUD Mn) | 9.44 | 13.13 | 15.04 | 16.27 | 16.94 |
Profit before tax (AUD Mn) | 8.19 | 11.79 | 13.46 | 14.59 | 15.37 |
Adjusted PBT — company definition (AUD Mn) | 8.19 | 11.79 | 13.46 | 14.59 | 16.06 |
Income tax expense (AUD Mn) | 2.10 | 3.61 | 3.97 | 4.25 | 4.88 |
Net profit after tax — total (AUD Mn) | 6.09 | 8.18 | 9.50 | 10.34 | 10.49 |
NPAT attributable to members (AUD Mn) | 6.08 | 7.69 | 8.89 | 10.38 | 10.49 |
EPS basic (A$ cents) | 4.5 | 5.6 | 6.4 | 7.4 | 7.4 |
EPS diluted (A$ cents) | 4.5 | 5.6 | 6.4 | 7.4 | 7.3 |
Dividends declared per share (A$ cents) | 2.5 | 3.3 | 3.9 | 4.5 | 4.5 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 43.3 | 41.6 | 44.2 | 48.4 | 49.3 |
EBIT (operating) margin (%) | 20.6 | 21.6 | 22.4 | 24.5 | 23.6 |
EBITDA margin (%) | 23.6 | 23.8 | 25.0 | 27.4 | 26.3 |
PBT margin (%) | 20.5 | 21.3 | 22.4 | 24.5 | 23.9 |
Net margin attributable (%) | 15.2 | 13.9 | 14.8 | 17.5 | 16.3 |
Effective tax rate (%) | 25.6 | 30.6 | 29.5 | 29.1 | 31.8 |
Total revenue growth (%) | 27.9 | 38.1 | 8.8 | -1.1 | 8.3 |
NPAT attributable growth (%) | 18.6 | 26.3 | 15.6 | 16.9 | 1.0 |
Dividend payout ratio on EPS (%) | 55.6 | 58.9 | 60.9 | 60.8 | 60.8 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 55.56 | 65.55 | 68.23 | 72.79 | 78.65 |
Cash and cash equivalents (AUD Mn) | 6.65 | 10.40 | 12.05 | 12.23 | 9.46 |
Trade and other receivables (AUD Mn) | 6.23 | 8.63 | 9.52 | 10.28 | 9.74 |
Inventories (AUD Mn) | 15.52 | 16.88 | 17.02 | 18.83 | 21.02 |
of which precious metals owned (AUD Mn) | 3.33 | 5.30 | not captured | 4.64 | 5.17 |
of which platinum on loan (AUD Mn) | 2.64 | 1.52 | not captured | 0.74 | 0.00 |
Property plant and equipment incl. ROU (AUD Mn) | 8.66 | 10.41 | 10.83 | 11.72 | 12.19 |
Goodwill and intangibles (AUD Mn) | 16.95 | 16.87 | 16.62 | 17.29 | 23.92 |
of which goodwill (AUD Mn) | not captured | not captured | 15.42 | 15.84 | 20.12 |
Short-term borrowings (AUD Mn) | 1.30 | 0.78 | 1.62 | 0.17 | 0.17 |
Long-term borrowings (AUD Mn) | 1.46 | 1.29 | 0.00 | 0.94 | 0.77 |
Total borrowings (AUD Mn) | 2.77 | 2.07 | 1.62 | 1.12 | 0.94 |
Lease liabilities current plus non-current (AUD Mn) | 0.75 | 2.24 | 1.76 | 1.76 | 1.40 |
Net debt excl. leases — derived (AUD Mn) | -3.88 | -8.33 | -10.43 | -11.12 | -8.52 |
Net debt incl. leases — derived (AUD Mn) | -3.13 | -6.09 | -8.67 | -9.35 | -7.12 |
Total current assets (AUD Mn) | 28.91 | 36.53 | 39.20 | 41.96 | 40.95 |
Total current liabilities (AUD Mn) | 9.66 | 11.62 | 10.45 | 9.54 | 8.34 |
Working capital — derived (AUD Mn) | 19.26 | 24.91 | 28.75 | 32.43 | 32.61 |
Total liabilities (AUD Mn) | 12.21 | 15.97 | 12.69 | 12.62 | 12.26 |
Total equity (AUD Mn) | 43.35 | 49.58 | 55.54 | 60.17 | 66.40 |
Cash Flow and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | 3.15 | 8.42 | 8.09 | 10.14 | 11.39 |
Payments for PP&E (AUD Mn) | 0.37 | 0.76 | 1.61 | 1.75 | 1.70 |
Capitalised R&D payments (AUD Mn) | 0.15 | 0.02 | 0.03 | 0.40 | 0.76 |
Other intangibles (AUD Mn) | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 |
Total capex incl. capitalised R&D (AUD Mn) | 0.52 | 0.78 | 1.64 | 2.15 | 2.59 |
Free cash flow — derived OCF less total capex (AUD Mn) | 2.63 | 7.63 | 6.45 | 7.99 | 8.80 |
Lease principal payments (AUD Mn) | 0.47 | 0.51 | 0.75 | 0.77 | 0.80 |
FCF after leases — derived (AUD Mn) | 2.16 | 7.13 | 5.70 | 7.22 | 8.00 |
Business acquisitions net of cash (AUD Mn) | 0.60 | 0.00 | 0.00 | 0.95 | 5.60 |
Transactions with NCI — Orbis buyout (AUD Mn) | 0.00 | 0.00 | 0.00 | 1.96 | 0.00 |
Cash dividends paid to members (AUD Mn) | 2.13 | 2.68 | 3.60 | 4.12 | 5.02 |
Dividends declared incl. DRP (AUD Mn) | 2.70 | 3.40 | 4.52 | 5.44 | 6.41 |
Share buybacks (AUD Mn) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
OCF to NPAT attributable conversion (x) | 0.52 | 1.10 | 0.91 | 0.98 | 1.09 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on closing equity (%) | 14.0 | 15.5 | 16.0 | 17.3 | 15.8 |
ROA on closing assets (%) | 10.9 | 11.7 | 13.0 | 14.3 | 13.3 |
ROIC — NOPAT over invested capital (%) | 15.3 | 19.0 | 20.3 | 20.3 | 17.5 |
Current ratio (x) | 2.99 | 3.14 | 3.75 | 4.40 | 4.91 |
Debt incl. leases to equity (x) | 0.08 | 0.09 | 0.06 | 0.05 | 0.04 |
Net debt incl. leases to EBITDA (x) | -0.33 | -0.46 | -0.58 | -0.57 | -0.42 |
Interest coverage EBIT over finance costs (x) | 121 | 54 | 47 | 57 | 116 |
Asset turnover revenue over closing assets (x) | 0.72 | 0.84 | 0.88 | 0.82 | 0.82 |
Days sales outstanding (days) | 57 | 57 | 58 | 63 | 55 |
Days inventory outstanding (days) | 250 | 191 | 185 | 224 | 235 |
Days payables outstanding (days) | 50 | 45 | 45 | 48 | 40 |
Cash conversion cycle (days) | 257 | 203 | 198 | 239 | 250 |
Income Statement
| Quarter metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Revenue (AUD Mn) | 13.1 | 15.6 | 13.9 | 16.8 | 15.3 | 16.0 | 15.8 | 17.2 | 21.1 |
Profit before tax (AUD Mn) | 3.2 | 3.7 | 3.4 | 4.3 | 3.4 | 4.1 | 3.7 | 4.2 | 4.4 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Australia-invoiced (AUD Mn) | 25.58 | 37.32 | 43.14 | 41.23 | 43.67 |
Canada-invoiced (AUD Mn) | 4.20 | 5.07 | 5.56 | 5.44 | 6.46 |
Europe-invoiced (AUD Mn) | 10.22 | 12.79 | 11.13 | 12.52 | 14.01 |
Total (AUD Mn) | 40.01 | 55.17 | 59.84 | 59.19 | 64.13 |
Region growth and share (%)
| Region growth and share (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia growth (%) | 45.9 | 15.6 | -4.4 | 5.9 |
Canada growth (%) | 20.6 | 9.8 | -2.3 | 18.7 |
Europe growth (%) | 25.1 | -13.0 | 12.4 | 11.9 |
Australia share (%) | 67.6 | 72.1 | 69.7 | 68.1 |
Canada share (%) | 9.2 | 9.3 | 9.2 | 10.1 |
Europe share (%) | 23.2 | 18.6 | 21.1 | 21.8 |
FY2026 Segment × Region Details
| FY2026 segment × region (AUD Mn) | Australia | Canada | Europe | Total |
|---|---|---|---|---|
Capital Equipment | 18.42 | 1.14 | 4.48 | 24.04 |
Precious Metals | 10.73 | 4.07 | 7.24 | 22.04 |
Consumables | 14.52 | 1.25 | 2.28 | 18.05 |
Total | 43.67 | 6.46 | 14.01 | 64.13 |
Revenue by Region
| Capital Equipment by region (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Australia (AUD Mn) | 7.12 | 13.92 | 15.69 | 15.80 |
Canada (AUD Mn) | 0.39 | 0.77 | 0.81 | 0.63 |
Europe (AUD Mn) | 2.69 | 2.86 | 4.06 | 4.41 |
Revenue by Region by Precious Metals by Region
| Precious Metals by region (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Australia (AUD Mn) | 8.15 | 9.32 | 11.77 | 9.96 |
Canada (AUD Mn) | 3.10 | 3.15 | 3.76 | 3.41 |
Europe (AUD Mn) | 6.45 | 8.22 | 4.92 | 5.72 |
Revenue by Region by Consumables by Region
| Consumables by region (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Australia (AUD Mn) | 10.31 | 14.08 | 15.68 | 15.48 |
Canada (AUD Mn) | 0.71 | 1.14 | 1.00 | 1.40 |
Europe (AUD Mn) | 1.08 | 1.71 | 2.14 | 2.39 |
Share price at 30 June (AUD)
| Share price at 30 June (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Closing price (AUD) | 0.57 | 1.17 | 1.345 | 1.84 | 1.73 |
Market capitalisation (AUD Mn) | 77.46 | 160.35 | 185.76 | 258.59 | 247.46 |
Return measure (approx., price only)
| Return measure (approx., price only) | Value |
|---|---|
Current price (14–15 Oct 2026) | A$1.87–1.92 |
Calendar 2026 YTD (from A$2.06 opening) | c.-9% to -7% |
1-year | c.-5% to -15% (aggregators reported -11% to -15% in Aug–Sep 2026; partially reversed by the 13 Oct 2026 rally) |
3-year (vs 30 Jun 2023 A$1.17) | c.+60% |
5-year (vs 30 Jun 2021 A$0.475) | c.+295% |
52-week range (as of Aug 2026) | A$1.60 – A$2.40 |
Since IPO (A$0.20, Oct 2006) | c.+840% |
Valuation Multiples
| Multiple | XRF Scientific | Basis |
|---|---|---|
Market capitalisation | c.A$269m | 143.7m shares × A$1.87 |
Enterprise value | c.A$262m | Market cap − cash A$9.46m + borrowings A$0.94m + leases A$1.40m |
P/E (trailing) | c.25.3x | A$1.87 ÷ 7.4c EPS |
EV/EBITDA (trailing) | c.15.5x | A$262m ÷ A$16.94m |
EV/Sales (trailing) | c.4.1x | A$262m ÷ A$64.4m |
P/B | c.4.0x | A$269m ÷ A$66.4m equity |
Dividend yield (fully franked) | c.2.4% (c.3.4% grossed-up) | 4.5c ÷ A$1.87 |
Analyst Ratings & Targets
| Broker | Rating | Target (AUD) | Date |
|---|---|---|---|
Canaccord Genuity | Buy | 2.30 | 19 Feb 2026 (from 2.35, Oct 2025) |
Dividend (A$ cents per share)
| Dividend (A$ cents per share) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Final dividend declared (A$ cents) | 2.5 | 3.3 | 3.9 | 4.5 | 4.5 |
Franking (%) | 100 | 100 | 100 | 100 | 100 |
Analyst Conclusions
Management guidance
No quantitative guidance is provided. Qualitative outlook (13 October 2026): the December 2026 quarter is expected to be strong, supported by new CGA instrument revenue and significant Orbis growth. FY2027 priorities (FY2026 results): ramp India and USA offices, grow Orbis and xrTGA, launch CGA instruments and consumables, develop gold-sector products, and pursue complementary acquisitions.
Consensus expectations
Detailed consensus is not publicly available. Aggregator summaries cite c.10% p.a. revenue growth and c.13% p.a. earnings growth. Analyst indicative frame (derived, not guidance): the September 2026 quarter run-rate (A$19.1m ex one-off sale) plus a full contribution from CGA (US$5.3m historical revenue ≈ A$8m) suggests FY2027 revenue potential in the low-to-mid A$70m range if Consumables recovery and Orbis growth persist; this should be treated as scenario analysis, not a forecast.
Bull case
-
Portfolio step-change into instruments: CGA adds c.US$5.3m of revenue acquired at c.0.75x sales, while xrTGA (A$1m FY2026, repeat orders) and Orbis (+66% in Sep 2026 quarter) give Capital Equipment multiple independent growth vectors beyond fusion machines.
-
Operating leverage on new offices: FY2026 absorbed A$0.69m of one-off acquisition/start-up costs and higher overheads; with India already profitable, FY2027 should see adjusted-to-statutory convergence and margin recovery, lifting EPS growth above revenue growth.
-
Cyclical tailwind with balance-sheet optionality: strong gold and copper prices, rising exploration financing and lab automation support sample volumes, while a net-cash balance sheet supports further accretive bolt-ons.
Bear case
-
Mining-cycle exposure: roughly two-thirds of invoicing is from Australia and demand is dominated by mining; a downturn in exploration or grade-control testing would hit both consumables and capital equipment simultaneously.
-
Stalled profit growth and rich multiple: statutory NPAT grew just 1% in FY2026, Consumables revenue fell 6%, and the dividend was held flat, yet the stock trades at c.25x trailing earnings and c.15.5x EV/EBITDA — demanding for a A$64m-revenue cyclical industrial with thin liquidity.
-
Execution risk in CS/OHN: transferring CGA production from Germany to Perth and competing against LECO and Eltra is a materially harder market than fusion consumables; the acquired business was non-core and sub-scale at Bruker.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Late Oct/Nov 2026 | 2026 AGM — board renewal signals, remuneration vote |
| Dec 2026 quarter | First CGA instruments produced in Perth; Orbis growth |
| Jan 2027 | December 2026 quarterly trading report |
| Feb 2027 | 1H FY2027 results — CGA contribution, adjusted vs statutory margins, Consumables recovery |
| Apr 2027 | March 2027 quarterly trading report |
| Aug 2027 | FY2027 results; dividend growth resumption |
| Ongoing | Platinum and lithium prices; gold price and exploration financing; AUD/USD/EUR; new-machine launches from the six-product pipeline; further bolt-on M&A; board renewal and diversity; India and USA office profitability |
Analyst verdict
XRF Scientific is a high-quality micro-to-small-cap industrial that has quietly built a defensible niche at the unglamorous but essential front end of elemental analysis. Over FY2022–FY2026 it compounded attributable earnings at roughly 15% per annum, expanded gross margin to almost 50%, sustained ROIC near 20% and funded every acquisition from internal cash while paying fully franked dividends. The razor-and-blade structure — machines pulling through flux and platinumware — is genuine and is reflected in Consumables' durable 37–38% PBT margins.
FY2026 was a transition year. Revenue reached a record A$64.4m, but statutory profit was flat as the company invested in India, the United States and the Bruker CGA acquisition. The September 2026 quarter suggests that investment is beginning to pay: underlying revenue grew roughly 25%, Consumables rebounded 27%, Orbis grew 66%, and India turned profitable almost immediately. If CGA production transfers smoothly to Perth in the December quarter, FY2027 should combine revenue growth from three distinct instrument lines with a reversal of FY2026's one-off cost drag.
The principal debates are cyclicality and valuation. The business remains tied to mining sample volumes, its disclosure is thin, governance is concentrated around long-tenured directors and a founder with related-party arrangements, and liquidity is limited. At c.25x trailing earnings the shares already discount a return to double-digit EPS growth.
On balance, the evidence supports a constructive but disciplined view: XRF is a structurally improving, cash-generative niche leader whose near-term catalysts (CGA launch, Orbis momentum, India/US ramp) are tangible and observable quarter by quarter. Investors should underwrite the story on delivered CGA revenue and Consumables stability through 1H FY2027, and treat any renewed mining-volume weakness or integration slippage as the key signals that the premium multiple is not justified.
All figures are sourced from XRF Scientific's audited annual reports (FY2023, FY2025, FY2026), ASX announcements through 13 October 2026, and identified secondary sources.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed / tenure | Qualifications | Prior / other roles | Shareholding (30 Jun 2026) | Independence (analyst view) |
|---|---|---|---|---|---|---|
Fred Grimwade | Non-Executive Chairman; Chair Remuneration Committee; member Audit & Governance | Director 1 May 2012 (14 yrs); Chairman since 29 Oct 2018 | BCom, LLB, MBA; FGIA; FAICD; FCSI | Principal & Director, Fawkner Capital; Director, Regal Cream Products (Bulla) from Dec 2025; NED Australian United Investment Co (since Mar 2014); former Chair CPT Global (to Nov 2023), former NED Select Harvests (to Feb 2023); prior GM roles at Colonial Agricultural Co, Colonial Group, Western Mining Corp, Goldman Sachs | 563,527 shares | Classified independent by tenure test caveat (>10 years) |
David Brown | Non-Executive Director; technical consultant to XRF Chemicals | 7 Jun 2004 (22 yrs) | BSc, BEc | Founder of XRF flux technology (1972); former Chief Chemist, Swan Brewery; former Chairman, Scientific Industries Council of WA | 8,224,200 shares (c.5.7%) | Not independent (founder, substantial holder, paid consultant, landlord) |
David Kiggins | Non-Executive Director; Chair Audit & Governance; member Remuneration | 1 May 2012 (14 yrs) | BSc (Hons); FCA (ICAEW); FCIS; MAICD | CFO, Sadleirs; former CFO Stealth Global and Heliwest; former FD Global Construction Services; former GM Bus Dev Automotive Holdings Group; Arthur Andersen | 217,181 shares | Independent subject to >10-year tenure caveat |
Vance Stazzonelli | Managing Director; Joint Company Secretary | MD 22 Feb 2018; CEO Aug 2012; joined Oct 2009 | BCom (Professional Accounting); CPA | XRF CFO (2009), COO (2011), CEO (2012) | 1,240,000 shares; 547,375 performance rights | Executive |
Executive Leadership Team
| Name | Role | Tenure | Qualifications |
|---|---|---|---|
Vance Stazzonelli | Managing Director | Since 2009 (MD 2018) | BCom, CPA |
Andrew Watson | Chief Financial Officer; Joint Company Secretary | Joined Aug 2012; Joint CoSec Aug 2013 | BCom; CA (CA ANZ); Grad Dip Applied Corporate Governance |
Brad Hunting | Co-founder and General Manager, Orbis Mining (non-KMP) | Orbis founder 2014 | — |
Sanjay Mitra | Country Manager, India (non-KMP) | From Feb 2026 | — |
“—” = not publicly disclosed.
Directors' Remuneration
| KMP FY2026 (AUD) | Cash salary | Cash bonus | Other | Super | LSL | Share-based (LTI) | Total |
|---|---|---|---|---|---|---|---|
Fred Grimwade | 108,482 | 0 | 0 | 13,018 | 0 | 0 | 121,500 |
David Brown | 65,625 | 0 | 255,520 | 7,875 | 0 | 0 | 329,020 |
David Kiggins | 75,089 | 0 | 0 | 9,011 | 0 | 0 | 84,100 |
Vance Stazzonelli | 448,200 | 110,200 | 0 | 30,540 | 12,905 | 170,201 | 772,046 |
Andrew Watson | 289,000 | 44,643 | 23,231 | 42,705 | 6,443 | 67,202 | 473,224 |
Directors' Remuneration (Annual)
| Total remuneration (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Vance Stazzonelli total (AUD) | 408,700 | 774,385 | 722,314 | 811,294 | 772,046 |
Andrew Watson total (AUD) | 248,996 | 403,943 | 470,246 | 475,264 | 473,224 |
All KMP total (AUD) | 1,060,708 | 1,633,405 | 1,684,041 | 1,797,700 | 1,779,890 |
Major Shareholders
| Holder | Shares | Stake (%) | Source / date |
|---|---|---|---|
David Brown (founder director) | 8,224,200 | c.5.7 | FY2026 Annual Report (30 Jun 2026) |
Michael Korber | 8,611,321 | 6.13 | Substantial holder notice (Feb 2025: reduced from 7.58% after selling 2,931,201 shares at c.A$1.61) |
Evelin Investments Pty Ltd | 7,315,216 | 5.21 | Aggregator data (2025) |
Charles Goode | 3,000,000 | 2.14 | Aggregator data (2025) |
Great Western Capital Pty Ltd | 2,939,374 | 2.09 | Aggregator data (2025) |
Stephen Prossor | 2,669,768 | 1.90 | Aggregator data (2025) |
Mandel Pty Ltd | 2,364,999 | 1.68 | Aggregator data (2025) |
Vance Stazzonelli | 1,240,000 | c.0.9 | FY2026 Annual Report |
Remaining top-10 holders | not captured | not captured | — |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Ownership | Overlap | Relative positioning |
|---|---|---|---|---|
Fusion fluxes and fusion machines | Malvern Panalytical (incl. Claisse fusion brand) | Spectris plc (agreed takeover by KKR in 2025; status should be verified) | Fusion machines, fluxes, XRF spectrometers | Global leader in XRF instrumentation; bundled solutions; much larger scale |
Fusion machines | Katanax | — | Electric fusion machines | Niche competitor in electric fusion |
Fluxes and sample-prep consumables | Fluxana (Germany) | Private | Fluxes, standards | European niche |
Fusion and pressing equipment | Herzog | — | Automated sample preparation | Strong in steel/cement automation |
Fusion, pressing, consumables | SPEX SamplePrep | Private (US) | Fusion fluxers, mills, presses | Strong US presence |
Platinum labware | Heraeus | Private (Germany) | Platinum crucibles and moulds | Global precious metals major |
Platinum labware | Johnson Matthey | LSE-listed | Platinum fabrication | Large precious metals group |
Platinum labware | Furuya Metal | Tokyo-listed | Platinum group metal products | Asian presence |
Laboratory crushers | Rocklabs | Scott Technology (NZX) | Lab jaw crushers, pulverisers | Direct Orbis competitor in mining labs |
Laboratory crushers | FLSmidth (Essa) | Nasdaq Copenhagen-listed | Lab crushers, sample prep systems | Large mining OEM |
Laboratory crushers and mills | Retsch | Verder Scientific (private) | Crushers, mills | Broad lab sample-prep range |
CS/OHN analysers | LECO | Private (US) | Combustion and inert-gas fusion analysers; TGA | Global leader in CS/OHN |
CS/OHN analysers | Eltra | Verder Scientific (private) | CS/OHN analysers | Strong European competitor |
CS/OHN analysers | Horiba | Tokyo-listed | EMIA/EMGA analysers | Strong in Asian steel |
CS/OHN and elemental | Elementar | Private (Germany) | Elemental analysers | Adjacent |
Thermogravimetric analysis | Mettler-Toledo; TA Instruments (Waters); Netzsch; LECO | Listed/private | TGA instruments | Broad thermal-analysis incumbents; xrTGA targets mining/industrial QC niche |
Peer Comparison FY2026
| Metric | XRF Scientific FY2026 | Bruker Corp FY2024 | Thermo Fisher FY2024 | Spectris FY2024 |
|---|---|---|---|---|
Revenue | A$64.4m | c.US$3.4bn | c.US$42.9bn | c.£1.3bn |
Revenue growth | 8.3% | — | — | — |
Operating margin | 23.6% (EBIT, derived) | — | — | — |
R&D intensity | ≥1.2% (capitalised only; total not disclosed) | — | — | — |
Relationship to XRF | — | Seller of CGA; XRF partner; XRF spectrometer OEM | XRF spectrometer OEM | Owner of Malvern Panalytical (direct competitor in fusion) |



